DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.